High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation

Bone Marrow Transplantation

Volumn 34, Issue 6, 2004, Pages 477-483

  Koenigsmann, Michael ^a   Mohren, M ^a   Jentsch Ullrich, K ^a   Franke, A ^a   Becker, E ^b   Heim, M ^b   Freund, M ^c,d   Casper, J ^c,d  

^a Division of Hematology/Oncology   (Germany)

^b Inst Transfus Med/Immunohematol   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Autologous PBPC transplantation; Relapsed high grade lymphoma; Tandem transplantation; Treosulfan

Indexed keywords

BENDAMUSTINE; CARMUSTINE; CISPLATIN; COUMARIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; HEPARIN; MELPHALAN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; THIOTEPA; TREOSULFAN; VINCRISTINE SULFATE;

ACIDOSIS; ADULT; ALOPECIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BLEEDING; BLOOD TOXICITY; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ERUPTION; DRUG FATALITY; DRUG MEGADOSE; FEMALE; FOLLICULAR LYMPHOMA; GASTROINTESTINAL TOXICITY; HEADACHE; HODGKIN DISEASE; HUMAN; IMMUNOBLASTIC LYMPHOMA; INFECTION; LARGE CELL LYMPHOMA; LEUKOCYTE COUNT; LIVER DYSFUNCTION; LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROBABILITY; REENTRY TACHYCARDIA; SEPSIS; STATISTICAL SIGNIFICANCE; STEM CELL MOBILIZATION; T CELL LYMPHOMA; THROMBOCYTE COUNT;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; RECURRENCE; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 4644288427     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704626     Document Type: Article

References (32)

1. Philip T, Guglielmi C, Hagenbeck A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
2. Bosly A, Gisselbrecht C. Therapy intensification with autologous transplantation in non-Hodgkin's lymphomas. Bull Cancer 2001; 88: 877-887.
3. Gupta V, Lazarus HM, Keating A. Myeloablative conditioning regimens for AML allografts: 30 years later. Bone Marrow Transplant 2003; 32: 969-978.
4. Jones RJ, Lee KS, Beschorner WE et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783.
5. Hänel M, Kröger N, Sonnenberg S et al. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol 2002; 81: 96-102.
6. Slattery JT, Risler LJ. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 1998; 20: 543-549.
7. Hassan M. The role of busulfan in bone marrow transplantation. Med Oncol 1999; 16: 166-176.
8. De La Camera R, Thomas JF, Figuera A et al. High dose busulfan and seizures. Bone Marrow Transplant 1991; 7: 363-364.
9. Feit PW. Stereoisomer 1,4-di-O-methansulfonyl-butan-1,2,3,4-tetrole. Tetrahedron Lett 1961; 20: 716-717.
10. Fenelly J. Treosulfan (hydroxybusulfan) in ovarian carcinoma. In: Nelson JD, Grassi C (eds). Current Chemotherapy and Infectious Disease. American Society for Microbiology: Washington, DC, 1980; pp 1683-1684.
11. Meden H, Wittkop Y, Kuhn W. Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: feasibility and toxicity. Anticancer Res 1997; 17: 2221-2224.
12. Scheulen ME, Hilger RA, Oberhoff C et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 2000; 6: 4209-4216.
13. Hilger RA, Harstrick A, Eberhardt W et al. Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors. Cancer Chemother Pharmacol 1998; 42: 99-104.
14. Meinhardt G, Dayyani F, Jahrsdorfer B et al. Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients. Br J Haematol 2003; 122: 892-899.
15. Fichtner I, Becker M, Baumgart J. Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL). Eur J Cancer 2003; 39: 801-807.
16. Casper J, Knauf W, Kiefer T et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 2003; 103: 725-731.
17. Jantunen E, Kuittinen T, Nousiainen T. BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy. Leukemia Lymphoma 2003; 44: 1151-1158.
18. Shimoni A, Smith TL, Aleman A et al. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant 2001; 27: 821-828.
19. Cheng T, Forsyth P, Chaudhry A et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 2003; 31: 679-685.
20. Lee JL, Gooley T, Bensinger W et al. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 1999; 5: 306-315.
21. Reiser M, Jostin A, Draube A et al. Successful peripheral blood stem cell mobilization with etoposide in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization. Bone Marrow Transplant 1999; 23: 1223-1228.
22. Junghanss C, Leithäuser M, Wilhem S et al. High-dose etoposide phosphate and G-CSF mobilizes peripheral blood stem cells in patients that previously failed to mobilize. Ann Hematol 2001; 80: 96-102.
23. Moskowitz CH, Bertino JR, Glassman JR et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3776-3785.
24. Bolwell BJ, Kalaycio M, Sobecks R et al. A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation. Bone Marrow Transplant 2002; 30: 587-591.
25. Guglielmi C, Gomez F, Philip T et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled in the PARMA trial. J Clin Oncol 1998; 16: 3264-3269.
26. Vose JM, Zhang MJ, Rowlings PA et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001; 19: 406-413.
27. Seropian S, Bahceci E, Cooper DL. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma. Bone Marrow Transplant 2003; 32: 763-769.
28. Bierman PJ, Sweetenham JW, Loberiza FR et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation - The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003; 21: 3744-3753.
29. Mollee P, Lazarus HM, Lipton J. Why aren't we performing more allografts for aggressive non-Hodgkin's lymphoma? Bone Marrow Transplant 2003; 31: 953-960.
30. Gisselbrecht C, Mounier N. Rituximab: enhancing outcome of autologous stem cell transplantation in non-Hodgkin's lymphoma. Semin Oncol 2003; 30: 28-33.
31. Benekli M, Hahn T, Shafi F et al. Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients. Bone Marrow Transplant 2003; 32: 139-143.
32. Shimoni A, Hardan I, Avigdor A et al. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. Br J Haematol 2003; 122: 457-464.